CN101252926A - 用于预防和治疗肥胖症及相关综合征的化合物与组合物 - Google Patents

用于预防和治疗肥胖症及相关综合征的化合物与组合物 Download PDF

Info

Publication number
CN101252926A
CN101252926A CNA2006800176430A CN200680017643A CN101252926A CN 101252926 A CN101252926 A CN 101252926A CN A2006800176430 A CNA2006800176430 A CN A2006800176430A CN 200680017643 A CN200680017643 A CN 200680017643A CN 101252926 A CN101252926 A CN 101252926A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
carbon atoms
group
alkylene group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800176430A
Other languages
English (en)
Chinese (zh)
Inventor
尼古拉斯·沙帕尔
帕特丽夏·麦克尼科尔
露西·耶特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innodia Inc
Original Assignee
Innodia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innodia Inc filed Critical Innodia Inc
Publication of CN101252926A publication Critical patent/CN101252926A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/28—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2006800176430A 2005-03-22 2006-03-22 用于预防和治疗肥胖症及相关综合征的化合物与组合物 Pending CN101252926A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66403805P 2005-03-22 2005-03-22
US60/664,038 2005-03-22

Publications (1)

Publication Number Publication Date
CN101252926A true CN101252926A (zh) 2008-08-27

Family

ID=37498818

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800176430A Pending CN101252926A (zh) 2005-03-22 2006-03-22 用于预防和治疗肥胖症及相关综合征的化合物与组合物

Country Status (8)

Country Link
US (1) US20060223884A1 (cg-RX-API-DMAC10.html)
EP (1) EP1874287A2 (cg-RX-API-DMAC10.html)
JP (1) JP2008538211A (cg-RX-API-DMAC10.html)
CN (1) CN101252926A (cg-RX-API-DMAC10.html)
AU (1) AU2006256442A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0611550A2 (cg-RX-API-DMAC10.html)
CA (1) CA2600954A1 (cg-RX-API-DMAC10.html)
WO (1) WO2006131836A2 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107998024A (zh) * 2017-12-20 2018-05-08 上海东晟源日化有限公司 一种含仙人掌精华具有深度保养功效的护肤用品
WO2022028615A1 (zh) * 2020-08-07 2022-02-10 郑州大学 治疗肿瘤的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060199853A1 (en) * 2005-02-18 2006-09-07 Charles Mioskowski Analogs of 4-hydroxyisoleucine and uses thereof
WO2007105730A1 (ja) * 2006-03-13 2007-09-20 Kyowa Hakko Kogyo Co., Ltd. インスリン抵抗性改善剤
WO2008044770A1 (en) * 2006-10-13 2008-04-17 Ajinomoto Co., Inc. Agent for suppression of gastric emptying comprising 4-hydroxyisoleucine
JPWO2008102671A1 (ja) * 2007-02-22 2010-05-27 味の素株式会社 4−ヒドロキシイソロイシンの精製方法
US8143014B2 (en) * 2007-10-02 2012-03-27 Mayo Foundation For Medical Education And Research CD38 and obesity
WO2010127439A1 (en) * 2009-05-06 2010-11-11 Bellus Health (International) Limited Ammo acid derivatives for the treatment of neuropathic pain
JP5703654B2 (ja) * 2010-09-22 2015-04-22 東レ・ファインケミカル株式会社 シス−4−ヒドロキシプロリンの製造法
CA2873439A1 (en) 2012-05-22 2013-11-28 Actelion Pharmaceuticals Ltd New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63218621A (ja) * 1987-03-09 1988-09-12 Kazuoki Tsuchiya 肥満症の予防・治療用組成物
US4912231A (en) * 1987-06-15 1990-03-27 E. R. Squibb & Sons, Inc. Process for preparing (trans)-4-phenyl-L-proline derivatives
FR2695317B1 (fr) * 1992-09-07 1995-03-10 Monal Lab Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
IL108583A (en) * 1994-02-07 1997-06-10 Yissum Res Dev Co Galactomannan emulsions and comestible products containing the same
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CA2206157C (en) * 1997-05-26 2000-06-13 Cheng, Peter Method of extraction of commercially valuable fractions of fenugreek
WO1999025370A1 (en) * 1997-11-18 1999-05-27 Nutricept, Inc. Methods for reducing the intestinal absorption of a caloric of compound in diabetics
UA59453C2 (uk) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. Похідні гідроксипіпеколат гідроксамової кислоти як інгібітори матричних металопротеїназ
FR2797767B1 (fr) * 1999-08-27 2002-06-14 Centre Nat Rech Scient Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
IN192689B (cg-RX-API-DMAC10.html) * 2000-02-14 2004-05-15 Rao Gariimella Bhaskar Dr
FR2806726B1 (fr) * 2000-03-27 2003-01-03 Centre Nat Rech Scient Procede de preparation de la (2s,3r,4s)-4-hydroxyisoleucine et de ses analogues
WO2003088947A1 (en) * 2002-04-22 2003-10-30 Experimental & Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
US7338675B2 (en) * 2002-05-10 2008-03-04 Tsi Health Sciences, Inc. Fenugreek seed bio-active compositions and methods for extracting same
US20050176827A1 (en) * 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
KR20050110018A (ko) * 2003-03-19 2005-11-22 교와 핫꼬 고교 가부시끼가이샤 당뇨병 치료제
JPWO2004087657A1 (ja) * 2003-03-28 2006-06-29 協和醗酵工業株式会社 抗肥満剤
FR2854629B1 (fr) * 2003-05-07 2005-06-17 Centre Nat Rech Scient Procede de synthese de la 4-hydroxyisoleucine et de ses derives
DK1638586T3 (da) * 2003-05-14 2008-06-23 Indus Biotech Pvt Ltd Synergistisk sammensætning til behandling af diabetes mellitus
FR2856297B1 (fr) * 2003-06-18 2005-08-05 Caster Utilisation de (2s,3r,4s)-4-hydroxyisoleucine dans des compositions cosmetiques pour application topique
WO2005039626A2 (en) * 2003-10-27 2005-05-06 Innodia Inc. Use of hydroxylated amino acids for treating diabetes
TW200528440A (en) * 2003-10-31 2005-09-01 Fujisawa Pharmaceutical Co 2-cyanopyrrolidinecarboxamide compound
US8337915B2 (en) * 2004-01-10 2012-12-25 S George Aburdeineh Fenugreek seed extract to lower blood cholesterol
WO2005080346A1 (en) * 2004-02-12 2005-09-01 Transtech Pharma, Inc. Substituted azole derivatives, compositions, and methods of use
US20050233014A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for affecting homeostasis and metabolism in a mammalian body
US20050226948A1 (en) * 2004-03-02 2005-10-13 Lee Steve S Methods for enhancing the transport of glucose into muscle
US20050233013A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for enhancing the transport of glucose for balancing blood sugar levels
US20060199853A1 (en) * 2005-02-18 2006-09-07 Charles Mioskowski Analogs of 4-hydroxyisoleucine and uses thereof
MX2007009985A (es) * 2005-02-18 2008-03-11 Innodia Inc Diastereoisomeros de 4-hidroxiisoleucina y usos de los mismos.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107998024A (zh) * 2017-12-20 2018-05-08 上海东晟源日化有限公司 一种含仙人掌精华具有深度保养功效的护肤用品
WO2022028615A1 (zh) * 2020-08-07 2022-02-10 郑州大学 治疗肿瘤的方法

Also Published As

Publication number Publication date
US20060223884A1 (en) 2006-10-05
AU2006256442A1 (en) 2006-12-14
BRPI0611550A2 (pt) 2009-01-13
WO2006131836A2 (en) 2006-12-14
WO2006131836A3 (en) 2007-10-04
CA2600954A1 (en) 2006-12-14
JP2008538211A (ja) 2008-10-16
EP1874287A2 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
EP4172145B1 (en) Tryptamine prodrugs as serotonin receptor activators for the treatment of e.g. depression
JP4947041B2 (ja) アミノカルボン酸誘導体およびその医薬用途
WO2006001463A1 (ja) S1p受容体結合能を有する化合物およびその用途
JPWO2003061698A1 (ja) 6−フルオロビシクロ[3.1.0]ヘキサン誘導体
JP2012136539A (ja) 甲状腺刺激ホルモン放出ホルモン類縁体及び使用方法
WO2016111347A1 (ja) 三環性スピロ化合物
US20100048545A1 (en) Compounds and Compositions for Use in the Prevention and Treatment of Disorders of Fat Metabolism and Obesity
CN101193852A (zh) 4-羟基异亮氨酸类似物及其用途
WO2017131149A1 (ja) テトラヒドロナフタレン誘導体
US20060223884A1 (en) Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
JP4788999B2 (ja) 分枝鎖カルボン酸化合物およびその用途
JP2018087189A (ja) 医薬用途
HK1123969A (en) Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
JPWO2005061492A1 (ja) 含窒素複素環化合物およびそれらを有効成分とする薬剤
HK1116160A (en) Analogs of 4-hydroxyisoleucine and uses thereof
JP2006016318A (ja) 2−プロピルオクタン酸の脳移行性向上プロドラッグおよびその用途
JP7593987B2 (ja) ネプリライシン(nep)阻害剤、特にアミノペプチダーゼn(apn)及びネプリライシン(nep)の混合阻害剤としてのn-ホルミルヒドロキシルアミン
WO2010113860A1 (ja) ビフェニル-環状アミン化合物
RU2776842C2 (ru) Применение агониста kor в комбинации с агонистом mor для получения лекарственного средства для лечения боли
MX2007011657A (en) Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
JP2006016319A (ja) プロドラッグ
HK40114252A (en) Tryptamine prodrugs
HK1120255A (en) Diastereoisomers of 4-hydroxyisoleucine and uses thereof
MX2011006655A (es) Compuestos de anima ciclica.
HK1240927A1 (en) Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1123969

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080827

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1123969

Country of ref document: HK